Autologous peripheral blood stem cell transplantation in the patients withhematologic malignancies and solid tumors

Objective To evaluate the long-term therapeutic effects of autologous perip heral blood stem cell transplantation (auto-PBSCT) on the treatment of hema tological and solid tumors. Methods Fifty-one patients were recruited in this auto-PBSCT study, in whic h several potentially important parameters were studied including the optim al time for stem cell collection, the dose of stem cell reinfusion, the tim e of hematopoietic reconstitution, the disease free survival (DFS) and over all survival (OS), complications related to transplantation, and maintenanc e chemotherapy after auto-PBSCT. Results After APBSCT, 3-year and 5-year survival rates of NHL were 83.3%; t hose of AML were 74.7%; those of MM were 37.9% and 19%; those of ALL were 4 0% and 0% respectively. Hematopoietic reconstitution was greatly promoted b y granulocyte colony stimulating factor (G-CSF). The mean time for patients ' neutrophil to recover up to > 0.5 x 10(9)/L after APBSCT was 11.14 days i n the group of the patients receiving G-CSF in contrast to 17.6 days in the group receiving no G-CSF. The most common complications of transplantation were fever, liver dysfunction and hypokalaemia, which were curable. No dea th was due to transplantation related complications. Conclusion Comparing with conventional chemotherapy, our study suggests tha t auto-PBSCT is a very important therapeutic option that can significantly improve the prognosis in the patients with hematological and solid tumors, especially in the patients with AML and NHL.